Biyapay
About Us
Corporate Profile
Management Team
Milestones
Awards
Our Vision
Affiliates
CTTQ Akesobio
Akeso Pharma
AD Pharmaceuticals
Contact Us
R&D and science
Technology Platform
Products Center
R&D and Manufacturing
Expanded Access Policy
Collaborations
Investor Relations
Financial Reports
Presentations
IR Monthly Reports
Announcements and Circulars
Corporate Governance
IR Calendar
IR Contact
Media
Akeso News
Media Coverage
Career
Social Recruitment
Campus Recruitment
简
|
EN
|
2023-09-28
Akeso and RemeGen Collaborate on Clinical Study Exploring the Potential of PD-1/CTLA-4 Bispecific Antibody with HER-2 ADC Combination Therapy in Gastric Cancer
2023-09-26
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
2023-08-30
Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF
2023-08-29
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC
2023-08-25
Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
2023-08-24
The NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab for Moderate-to-severe Plaque Psoriasis by China NMPA
2023-08-18
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
2023-08-06
The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC
2023-06-06
Akeso updated 2-year data from cadonilimab combined with chemotherapy in first line treatment of gastric cancer at 2023 ASCO meeting
2023-06-02
NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two indications
2023-03-16
Akeso Reported 2022 Annual Results
2023-03-14
Patient Enrollment Completed for Phase III Clinical Trial of Akeso’s Cadonilimab in Treatment of Gastric Cancer
«
5
6
7
8
9
10
11
12
13
»
